<DOC>
	<DOC>NCT00438815</DOC>
	<brief_summary>The study objective was to evaluate the safety and efficacy of repeat use of C1INH-nf for the treatment of acute HAE attacks.</brief_summary>
	<brief_title>Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks</brief_title>
	<detailed_description>A total of 113 subjects were enrolled in the study. One-hundred-one (101) subjects received C1INH-nf for the treatment of 1 or more HAE attacks and were analyzed for efficacy. The study design also allowed for short-term prophylaxis with C1INH-nf prior to emergency or non-cosmetic surgical or dental procedures, and an additional 12 subjects received C1INH-nf only for this purpose. All 113 subjects were exposed to C1INH-nf and analyzed for safety.</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>This study was open to all subjects who: Completed participation in LEVP20051/A (NCT00289211) and were not participating in LEVP20051/B (NCT01005888), any time after the 3day telephone followup Completed participation in LEVP20051/B any time after the final prophylactic therapy in Part B Were enrolled but not randomized in LEVP20051/A after Part A was closed Were excluded from LEVP20051 for any of the following reasons: Pregnancy or lactation Age less than 6 years Narcotic addiction Presence of antiC1INH autoantibodies Were not enrolled in LEVP20051 after enrollment in LEVP20051 was closed, under the following circumstances: Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or Had a known HAEcausing C1INH mutation, or Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator History of allergic reaction to C1INH or other blood products Participated in any other investigational drug study within the past 30 days Received blood or a blood product in the past 60 days other than C1INHnf</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hereditary angioedema</keyword>
	<keyword>C1 esterase inhibitor (human)</keyword>
</DOC>